ClinicalTrials.gg
CompletedNCT04676867Updated Dec 7, 2022Results posted

Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19

A Phase 2 interventional study of Dalcetrapib and Placebo in Covid19, sponsored by DalCor Pharmaceuticals. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-12-07.

Sponsored by DalCor Pharmaceuticals · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
227
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 289 studies in COVID-19 with a site in Canada — 24 open to participants now, 36 under way, 8 of them phase 3. COVID-19 · Canada.

Enrollment
79th of 200
227 · median 120
Started
2021
with 94 others
Phase 2
28 of 289
3 open now
Registered
134th of 289
by date

Among the 289 studies in COVID-19 with a site in Canada, this one is the 79th largest by enrollment of the 200 interventional ones that give a count, is one of 95 that started in 2021, is one of 28 in phase 2, and was the 134th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

24 of the 289 studies in COVID-19 with a site in Canada are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 289 studies in COVID-19 with a site in Canada, or all of them as a file.
02

Study summary

This study is a placebo-controlled, Phase 2a proof-of-concept clinical study which will evaluate efficacy and safety of dalcetrapib in outpatients patients with mild to moderate, symptomatic, confirmed COVID 19.

03

Conditions studied

  • Covid19

Browse trials for

Keywords

  • COVID-19
  • Coronavirus disease
  • Dalcetrapib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must satisfy all of the following criteria unless otherwise stated:

    1. Willing and able to provide
    2. Male or female patients > 18 years of age on the day of informed consent
    3. Have received a confirmed diagnosis of COVID-19 (positive for SARS CoV 2), as assessed by PCR or point-of-care within 72 hours of first dose on Day 1
    4. Have mild to moderate signs or symptoms of COVID-19 with onset within 5 days of first dose on Day 1, at least two of the following symptoms:

      • stuffy or runny nose
      • sore throat
      • shortness of breath
      • cough
      • fatigue
      • myalgia
      • headache
      • chills or shivering
      • feeling hot or feverish
      • nausea
      • vomiting
      • diarrhea
      • anosmia
      • ageusia
    5. Outpatient with COVID-19 disease (not requiring oxygen therapy [WHO COVID-19 Clinical Improvement Ordinal Scale, score of 3])
    6. Patient is aware of the nature of this study and willing to comply with protocol treatments, blood tests, and other evaluations listed in the informed consent form (ICF).

Exclusion criteria

Exclusion Criteria:

  • Patients will be excluded from the study if they satisfy any of the following criteria unless otherwise stated:

    1. Females who are pregnant (negative pregnancy test required for all women of child bearing potential at Screening) or breast-feeding
    2. Male patients and women of (women who are not surgically sterile or defined as amenorrhea for >12 months) who are not using at least one protocol specified method of
    3. Severe COVID-19 disease as defined by the WHO COVID-19 Clinical Improvement Ordinal Scale, scores of 5 (non invasive ventilation or high-flow oxygen), 6 (intubation and mechanical ventilation), or 7 (ventilation + additional organ support pressors, renal replacement therapy [RRT], extracorporeal membrane oxygenation [ECMO])
    4. Expected survival less than 72 hours
    5. Peripheral capillary oxygen saturation (SpO2) \<90% while breathing room air
    6. Treatment with other drugs thought to possibly have activity against SARS CoV 2 infection like remdesivir, favipiravir, within 7 days prior to enrollment or concurrently
    7. History of abuse of drugs or alcohol that could interfere with adherence to study requirements as judged by the Investigator
    8. Use of any other concurrent drugs while participating in the present study
    9. Patient requires frequent or prolonged use of systemic (≥20 mg of prednisone/day or equivalent for >4 weeks) or other drugs (e.g., for organ transplantation or conditions)
    10. Known renal disease with an estimated (eGFR) \<50 mL/min based on local laboratory results
    11. Patients with clinically apparent liver disease, e.g., jaundice, cholestasis, hepatic synthetic impairment, or active hepatitis
    12. (ALT) or aspartate transaminase (AST) >3 × (ULN) or alkaline phosphatase or levels > 2 × ULN based on local laboratory results
    13. Co administration of clinical doses of orlistat with dalcetrapib
    14. Inability to swallow oral medications or a gastrointestinal disorder with diarrhea (e.g., Crohn's disease) or malabsorption at Screening
    15. Any other medical condition or laboratory abnormality that, in the opinion of the Investigator, would jeopardize the safety of the patient or potentially impact patient compliance or the safety/efficacy observations in the study
    16. History of an allergic reaction or to the study drug or any component of the study drug formulation.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
227 participants (actual)

Study arms

  • Active comparator
    900 mg dose

    Patients will receive Dalcetrapib 900 mg for 10 days

    Drug: Dalcetrapib

  • Active comparator
    1800 mg dose

    Patients will receive Dalcetrapib 1800 mg for 10 days

    Drug: Dalcetrapib

  • Active comparator
    3600 mg dose

    Patients will receive Dalcetrapib 3600 mg for 10 days

    Drug: Dalcetrapib

  • Placebo comparator
    Placebo tablets

    Patients will receive Placebo for 10 days

    Other: Placebo

Interventions

  • Dalcetrapib 300 mg Film-Coated Tablets

  • OtherPlacebo

    Placebo Tablets

06

What researchers measure

Primary outcomes

  1. Time to Sustained Clinical Resolution of Symptoms of COVID-19 (Excluding Cough, Sense of Smell and Taste) in Subjects With Confirmed, Mild to Moderate, Symptomatic COVID-19 Treatment With Dalcetrapib

    Sustained clinical resolution is defined as occurring when no key COVID-19 related symptom has a score higher than 1 over a 72-hour period (as documented using an electronic patient-reported outcome \[ePRO\] instrument), except for sense of smell and taste where the score should be 0 over a 72-hour period. The time to resolution was taken as the time from randomization until the first day of the last 72-hour period where the patient met the definition of resolution within 28 days. Patients who did not meet the definition of resolution 28 days after randomization were considered not resolved. The scale is "Assessment of 14 Common COVID-19-Related Symptoms: Items and Response" from the Food and Drug Administration (FDA). The symptoms are scored as on a scale of 0 to 3 for 12 of the symptoms where 0 is none and on a scale of 0 to 2 for the two other symptoms where 0 is "as usual". A higher score is a worse outcome.

    Time frame: 28 days

Secondary outcomes

  1. Change From Baseline in log10 Viral Load (Saliva)

    Log10 viral load, as assessed using the saliva, was summarized by treatment group using descriptive statistics (N, mean, median, standard deviation, minimum, and maximum) for each visit as well as for changes from baseline where an 80% CI were also presented. A repeated ANCOVA model was used for the data shown below, showing the mean changes from baseline to study visits (Day 3, Day 5, Day 10, and Day 28/EOS) in log10 viral load including treatment groups by study visit interaction, baseline value of log10 viral load and baseline value of log10 viral load by study visit interaction.

    Time frame: Screening/Baseline (Day -2 to Day -1), Day 3, Day 5, Day 10, and Day 28/End of Study (EOS)

  2. Change From Baseline in log10 Viral Load (Nasal Swab)

    Log10 viral load, as assessed using the nasal swab, was summarized by treatment group using descriptive statistics (N, mean, median, standard deviation, minimum, and maximum) for each visit as well as for changes from baseline where an 80% CI were also presented. A repeated ANCOVA model was used for the data shown below, showing the mean changes from baseline to study visits (Day 3, Day 5, Day 10, and Day 28/EOS) in log10 viral load including treatment groups by study visit interaction, baseline value of log10 viral load and baseline value of log10 viral load by study visit interaction.

    Time frame: Screening/Baseline (Day -2 to Day -1), Day 3, Day 5, Day 10, and Day 28/End of Study (EOS)

  3. Time to Sustained Complete Clinical Resolution of Symptoms in Subjects With Confirmed, Mild to Moderate, Symptomatic COVID-19 Treatment With Dalcetrapib

    Sustained clinical resolution is defined as occurring when no key COVID-19 related symptom has a score higher than 1 over a 72-hour period (as documented using an electronic patient-reported outcome \[ePRO\] instrument). The time to resolution was taken as the time from randomization until the first day of the last 72-hour period where the patient met the definition of resolution within 28 days. Patients who did not meet the definition of resolution 28 days after randomization were considered not resolved. The scale is "Assessment of 14 Common COVID-19-Related Symptoms: Items and Response" from the Food and Drug Administration (FDA). The symptoms are scored as on a scale of 0 to 3 for 12 of the symptoms where 0 is none and on a scale of 0 to 2 for the two other symptoms where 0 is "as usual". A higher score is a worse outcome.

    Time frame: 28 days

  4. Viral Clearance Using Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) Polymerase Chain Reaction (PCR)

    Viral clearance based on polymerase chain reaction (PCR) test for Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) using nasal swab and saliva samples was performed on the intention-to-treat (ITT) population. Viral clearance was summarized by treatment group using Kaplan-Meier methods. Median and associated 80% confidence interval (CI) was presented. The number and percentage of patients who did not show viral clearance, did show viral clearance, and patients censored were presented.

    Time frame: Day 1 to Day 28

  5. Time to Complete Clinical Resolution (Excluding Cough, Sense of Smell and Taste) Defined in the Same Way as the Primary Endpoint, But Considering That All Symptoms Must Resolve to a Score of 0 for 72 Hours

    Complete clinical resolution is defined as occurring when no key COVID-19 related symptom (excluding cough, sense of smell and taste) has a score higher than 0 over a 72-hour period. The time to resolution was taken as the time from randomization until the first day of the last 72 hour period where the patient met the definition of resolution within 28 days. Patients who did not meet the definition of resolution 28 days after randomization were considered not resolved. The scale is "Assessment of 14 Common COVID-19-Related Symptoms: Items and Response" was used. The symptoms are scored as on a scale of 0 to 3 for 12 of the symptoms where 0 is none and on a scale of 0 to 2 for the two other symptoms where 0 is "as usual". A higher score is a worse outcome.

    Time frame: 28 days

  6. Time to Complete Clinical Resolution

    Sustained clinical resolution is defined as occurring when no key COVID-19 related symptom has a score higher than 0 over a 72-hour period. The time to resolution was taken as the time from randomization until the first day of the last 72 hour period where the patient met the definition of resolution within 28 days. Patients who did not meet the definition of resolution 28 days after randomization were considered not resolved. The scale is "Assessment of 14 Common COVID-19-Related Symptoms: Items and Response" was used. The symptoms are scored as on a scale of 0 to 3 for 12 of the symptoms where 0 is none and on a scale of 0 to 2 for the two other symptoms where 0 is "as usual". A higher score is a worse outcome. Resolution must have occurred within 28 days. Time of resolution of 29 days was imputed in censored subjects.

    Time frame: 28 days

  7. Change From Baseline in Coronavirus Disease of 2019 (COVID-19) Total Symptom Severity Score Collected at All Time Points

    COVID-19 total symptom severity score was summarized by treatment group using descriptive statistics (N, mean, median, standard deviation, minimum, and maximum) for each visit as well as for changes from baseline where an 80% confidence interval (CI) was also presented. Mean changes from baseline were analyzed using a repeated measures ANCOVA model. The scale is "Assessment of 14 Common COVID-19-Related Symptoms: Items and Response" from the Food and Drug Administration (FDA) document "Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment Guidance for Industry". Symptoms are scored as on a scale of 0 to 3 for 12 the symptoms and on a scale of 0 to 2 for two symptoms. The sum of all 14 symptom scores is reported, where 0 is the minimum and 40 is the maximum. A higher score is a worse outcome.

    Time frame: Baseline, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10, Day 14 (follow-up visit 1), and Day 28 (end of study / follow-up visit 2)

  8. Scoring of World Health Organization (WHO) Clinical Outcome Scale (9-point Scale) at Screening, Days 1, 3, 5, End of Treatment (Day 10), Follow-Up Visit (Day 14), and Day 28

    The number and percentage of patients for each WHO clinical outcome score was summarized. Scores were compared using the Mann-Whitney-Wilcoxon test. This scale is called the "WHO Clinical Outcome Scale". It is scored from 0 to 9 where 9 is the most severe disease presentation. A higher score is a worse outcome.

    Time frame: Screening (Day -2 to Day -1), Days 1, 3, 5, End of Treatment (Day 10), Follow-Up Visit (Day 14), and Day 28

  9. Rate of Hospitalization Through Day 28

    The analysis of this endpoint was performed on the intention-to-treat (ITT) population. The percentage of patients who were hospitalized was compared using a binary logistic regression analysis. The model included only the treatment group. The results were presented as odds ratios, with associated 80% CIs and p-value.

    Time frame: Day 1 to Day 28

  10. Rate of Progression to Oxygen Therapy Through Day 28

    The analysis of this endpoint was performed on the intention-to-treat (ITT) population. The number and percentage of patients who progressed to oxygen therapy was presented. The percentage of patients who had progressed to oxygen therapy was compared using a binary logistic regression analysis. The model included only the treatment group. The results were presented as odds ratios, with associated 80% confidence intervals (CIs) and p-value.

    Time frame: Day 1 to Day 28

  11. Type of Oxygen Therapy Received Through Day 28

    The analysis of this endpoint was performed on the intention-to-treat (ITT) population and only on those who received oxygen therapy. The number and percentage of patients who received different types of oxygen therapy was presented using descriptive statistics.

    Time frame: Day 1 to Day 28

  12. Duration of Hospitalization

    The duration of hospitalization was performed on the intention-to-treat (ITT) population in subjects who were hospitalized. Duration of hospitalization was summarized by treatment group using descriptive statistics (N, mean, median, standard deviation, Q1, Q3, minimum, and maximum). An ANOVA model was performed to analyze the difference between treatment groups. The model included only the treatment group. Contrasts under this model allowed for the comparisons across treatment groups. The results were presented as mean treatment difference with associated 80% confidence interval (CI) and p-value.

    Time frame: Day 1 through Day 28

  13. Mortality Rate by Day 28

    The analysis of this endpoint was performed on the intention-to-treat (ITT) population. The number and percentage of patients who died was presented. The percentage of patients who died was compared using a binary logistic regression. The model included only the treatment group. Contrasts under this model allowed for the comparisons across treatment groups. The results were presented as odds ratios, with associated 80% CIs and p-values.

    Time frame: Day 1 to Day 28

07

Results

Posted Dec 7, 2022
Limitations and caveats
Small sample size, remote study, and patients were self-sampling for the polymerase chain reaction (PCR) testing albeit under supervision.

Participant flow

Participant flow — Overall Study
MilestonePlacebo Tablets900 mg Dose1800 mg Dose3600 mg Dose
Started56565657
Entered study and received at least 1 dose of study medication53554852
Completed53544551
Not completed32116
Withdrew: Screen failure0062
Withdrew: Death0010
Withdrew: Withdrawal by subject2244
Withdrew: Lost to follow-up1000

Outcome measures

PrimaryTime to Sustained Clinical Resolution of Symptoms of COVID-19 (Excluding Cough, Sense of Smell and Taste) in Subjects With Confirmed, Mild to Moderate, Symptomatic COVID-19 Treatment With Dalcetrapib

Sustained clinical resolution is defined as occurring when no key COVID-19 related symptom has a score higher than 1 over a 72-hour period (as documented using an electronic patient-reported outcome \[ePRO\] instrument), except for sense of smell and taste where the score should be 0 over a 72-hour period. The time to resolution was taken as the time from randomization until the first day of the last 72-hour period where the patient met the definition of resolution within 28 days. Patients who did not meet the definition of resolution 28 days after randomization were considered not resolved. The scale is "Assessment of 14 Common COVID-19-Related Symptoms: Items and Response" from the Food and Drug Administration (FDA). The symptoms are scored as on a scale of 0 to 3 for 12 of the symptoms where 0 is none and on a scale of 0 to 2 for the two other symptoms where 0 is "as usual". A higher score is a worse outcome.

Time frame:
28 days
Reported as:
Median · days
Time to Sustained Clinical Resolution of Symptoms of COVID-19 (Excluding Cough, Sense of Smell and Taste) in Subjects With Confirmed, Mild to Moderate, Symptomatic COVID-19 Treatment With Dalcetrapib
daysPlacebo Tablets900 mg Dose1800 mg Dose3600 mg Dose
Time to Sustained Clinical Resolution of Symptoms of COVID-19 (Excluding Cough, Sense of Smell and Taste) in Subjects With Confirmed, Mild to Moderate, Symptomatic COVID-19 Treatment With Dalcetrapib9.0 (8.0 to 14.0)9.0 (8.0 to 10.0)9.5 (8.0 to 14.0)10.0 (9.0 to 11.0)
Statistical analysis
  • Placebo Tablets vs 900 mg Dose vs 1800 mg Dose vs 3600 mg Dose · Log Rank · p = 0.2
SecondaryChange From Baseline in log10 Viral Load (Saliva)

Log10 viral load, as assessed using the saliva, was summarized by treatment group using descriptive statistics (N, mean, median, standard deviation, minimum, and maximum) for each visit as well as for changes from baseline where an 80% CI were also presented. A repeated ANCOVA model was used for the data shown below, showing the mean changes from baseline to study visits (Day 3, Day 5, Day 10, and Day 28/EOS) in log10 viral load including treatment groups by study visit interaction, baseline value of log10 viral load and baseline value of log10 viral load by study visit interaction.

Time frame:
Screening/Baseline (Day -2 to Day -1), Day 3, Day 5, Day 10, and Day 28/End of Study (EOS)
Reported as:
Mean · log10 viral titers
Change From Baseline in log10 Viral Load (Saliva)
log10 viral titersPlacebo Tablets900 mg Dose1800 mg Dose3600 mg Dose
Day 3-0.77 (-1.04 to -0.49)-0.79 (-1.04 to -0.54)-0.61 (-0.89 to -0.32)-0.79 (-1.07 to -0.51)
Day 5-1.45 (-1.72 to -1.18)-1.50 (-1.76 to -1.25)-1.45 (-1.73 to -1.17)-1.27 (-1.55 to -0.99)
Day 10-3.43 (-3.79 to -3.08)-3.24 (-3.55 to -2.92)-3.01 (-3.38 to -2.65)-3.23 (-3.61 to -2.85)
Day 28/End of Study-5.16 (-5.40 to -4.91)-4.96 (-5.20 to -4.72)-5.30 (-5.57 to -5.03)-5.16 (-5.42 to -4.90)
Statistical analysis
  • Placebo Tablets vs 900 mg Dose vs 1800 mg Dose vs 3600 mg Dose · ANCOVA · p = 0.2
SecondaryChange From Baseline in log10 Viral Load (Nasal Swab)

Log10 viral load, as assessed using the nasal swab, was summarized by treatment group using descriptive statistics (N, mean, median, standard deviation, minimum, and maximum) for each visit as well as for changes from baseline where an 80% CI were also presented. A repeated ANCOVA model was used for the data shown below, showing the mean changes from baseline to study visits (Day 3, Day 5, Day 10, and Day 28/EOS) in log10 viral load including treatment groups by study visit interaction, baseline value of log10 viral load and baseline value of log10 viral load by study visit interaction.

Time frame:
Screening/Baseline (Day -2 to Day -1), Day 3, Day 5, Day 10, and Day 28/End of Study (EOS)
Reported as:
Mean · log10 viral titers
Change From Baseline in log10 Viral Load (Nasal Swab)
log10 viral titersPlacebo Tablets900 mg Dose1800 mg Dose3600 mg Dose
Day 3-0.94 (-1.18 to -0.71)-1.17 (-1.39 to -0.94)-0.84 (-1.09 to -0.60)-0.92 (-1.17 to -0.68)
Day 5-1.87 (-2.15 to -1.60)-2.25 (-2.53 to -1.98)-1.47 (-1.76 to -1.17)-2.00 (-2.29 to -1.71)
Day 10-4.76 (-5.08 to -4.45)-4.42 (-4.72 to -4.11)-3.87 (-4.22 to -3.52)-4.23 (-4.59 to -3.87)
Day 28/End of Study-6.24 (-6.32 to -6.15)-6.29 (-6.38 to -6.21)-6.26 (-6.36 to -6.17)-6.34 (-6.43 to -6.25)
Statistical analysis
  • Placebo Tablets vs 900 mg Dose vs 1800 mg Dose vs 3600 mg Dose · ANCOVA · p = 0.2
SecondaryTime to Sustained Complete Clinical Resolution of Symptoms in Subjects With Confirmed, Mild to Moderate, Symptomatic COVID-19 Treatment With Dalcetrapib

Sustained clinical resolution is defined as occurring when no key COVID-19 related symptom has a score higher than 1 over a 72-hour period (as documented using an electronic patient-reported outcome \[ePRO\] instrument). The time to resolution was taken as the time from randomization until the first day of the last 72-hour period where the patient met the definition of resolution within 28 days. Patients who did not meet the definition of resolution 28 days after randomization were considered not resolved. The scale is "Assessment of 14 Common COVID-19-Related Symptoms: Items and Response" from the Food and Drug Administration (FDA). The symptoms are scored as on a scale of 0 to 3 for 12 of the symptoms where 0 is none and on a scale of 0 to 2 for the two other symptoms where 0 is "as usual". A higher score is a worse outcome.

Time frame:
28 days
Reported as:
Median · days
Time to Sustained Complete Clinical Resolution of Symptoms in Subjects With Confirmed, Mild to Moderate, Symptomatic COVID-19 Treatment With Dalcetrapib
daysPlacebo Tablets900 mg Dose1800 mg Dose3600 mg Dose
Time to Sustained Complete Clinical Resolution of Symptoms in Subjects With Confirmed, Mild to Moderate, Symptomatic COVID-19 Treatment With Dalcetrapib28.0 (16.0 to 28.0)28.0 (15.0 to 28.0)28.0 (28.0 to 29.0)28.0 (28.0 to 28.0)
Statistical analysis
  • Placebo Tablets vs 900 mg Dose vs 1800 mg Dose vs 3600 mg Dose · Log Rank · p = 0.2
SecondaryViral Clearance Using Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) Polymerase Chain Reaction (PCR)

Viral clearance based on polymerase chain reaction (PCR) test for Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) using nasal swab and saliva samples was performed on the intention-to-treat (ITT) population. Viral clearance was summarized by treatment group using Kaplan-Meier methods. Median and associated 80% confidence interval (CI) was presented. The number and percentage of patients who did not show viral clearance, did show viral clearance, and patients censored were presented.

Time frame:
Day 1 to Day 28
Reported as:
Count of participants · Participants
Viral Clearance Using Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2) Polymerase Chain Reaction (PCR)
ParticipantsPlacebo Tablets900 mg Dose1800 mg Dose3600 mg Dose
Viral Clearance (saliva) — Yes1210914
Viral Clearance (saliva) — No41443936
Viral Clearance (nasal swab) — Yes25221214
Viral Clearance (nasal swab) — No28323636
Statistical analysis
  • Placebo Tablets vs 900 mg Dose vs 1800 mg Dose vs 3600 mg Dose · Log Rank · p = 0.2
SecondaryTime to Complete Clinical Resolution (Excluding Cough, Sense of Smell and Taste) Defined in the Same Way as the Primary Endpoint, But Considering That All Symptoms Must Resolve to a Score of 0 for 72 Hours

Complete clinical resolution is defined as occurring when no key COVID-19 related symptom (excluding cough, sense of smell and taste) has a score higher than 0 over a 72-hour period. The time to resolution was taken as the time from randomization until the first day of the last 72 hour period where the patient met the definition of resolution within 28 days. Patients who did not meet the definition of resolution 28 days after randomization were considered not resolved. The scale is "Assessment of 14 Common COVID-19-Related Symptoms: Items and Response" was used. The symptoms are scored as on a scale of 0 to 3 for 12 of the symptoms where 0 is none and on a scale of 0 to 2 for the two other symptoms where 0 is "as usual". A higher score is a worse outcome.

Time frame:
28 days
Reported as:
Median · days
Time to Complete Clinical Resolution (Excluding Cough, Sense of Smell and Taste) Defined in the Same Way as the Primary Endpoint, But Considering That All Symptoms Must Resolve to a Score of 0 for 72 Hours
daysPlacebo Tablets900 mg Dose1800 mg Dose3600 mg Dose
Time to Complete Clinical Resolution (Excluding Cough, Sense of Smell and Taste) Defined in the Same Way as the Primary Endpoint, But Considering That All Symptoms Must Resolve to a Score of 0 for 72 Hours28.0 (28.0 to 29.0)28.0 (28.0 to 28.0)28.0 (28.0 to 29.0)28.0 (28.0 to 29.0)
Statistical analysis
  • Placebo Tablets vs 900 mg Dose vs 1800 mg Dose vs 3600 mg Dose · Log Rank · p = 0.2
SecondaryTime to Complete Clinical Resolution

Sustained clinical resolution is defined as occurring when no key COVID-19 related symptom has a score higher than 0 over a 72-hour period. The time to resolution was taken as the time from randomization until the first day of the last 72 hour period where the patient met the definition of resolution within 28 days. Patients who did not meet the definition of resolution 28 days after randomization were considered not resolved. The scale is "Assessment of 14 Common COVID-19-Related Symptoms: Items and Response" was used. The symptoms are scored as on a scale of 0 to 3 for 12 of the symptoms where 0 is none and on a scale of 0 to 2 for the two other symptoms where 0 is "as usual". A higher score is a worse outcome. Resolution must have occurred within 28 days. Time of resolution of 29 days was imputed in censored subjects.

Time frame:
28 days
Reported as:
Median · days
Time to Complete Clinical Resolution
daysPlacebo Tablets900 mg Dose1800 mg Dose3600 mg Dose
Time to Complete Clinical Resolution29.0 (28.0 to 29.0)28.0 (28.0 to 29.0)29.0 (28.0 to 29.0)28.5 (28.0 to 29.0)
Statistical analysis
  • Placebo Tablets vs 900 mg Dose vs 1800 mg Dose vs 3600 mg Dose · Log Rank · p = 0.2
SecondaryChange From Baseline in Coronavirus Disease of 2019 (COVID-19) Total Symptom Severity Score Collected at All Time Points

COVID-19 total symptom severity score was summarized by treatment group using descriptive statistics (N, mean, median, standard deviation, minimum, and maximum) for each visit as well as for changes from baseline where an 80% confidence interval (CI) was also presented. Mean changes from baseline were analyzed using a repeated measures ANCOVA model. The scale is "Assessment of 14 Common COVID-19-Related Symptoms: Items and Response" from the Food and Drug Administration (FDA) document "Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment Guidance for Industry". Symptoms are scored as on a scale of 0 to 3 for 12 the symptoms and on a scale of 0 to 2 for two symptoms. The sum of all 14 symptom scores is reported, where 0 is the minimum and 40 is the maximum. A higher score is a worse outcome.

Time frame:
Baseline, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7, Day 8, Day 9, Day 10, Day 14 (follow-up visit 1), and Day 28 (end of study / follow-up visit 2)
Reported as:
Mean · score on a scale
Change From Baseline in Coronavirus Disease of 2019 (COVID-19) Total Symptom Severity Score Collected at All Time Points
score on a scalePlacebo Tablets900 mg Dose1800 mg Dose3600 mg Dose
Baseline10.70 ± 4.9811.11 ± 4.3410.88 ± 4.639.02 ± 3.92
Day 210.30 ± 5.3510.76 ± 4.5811.55 ± 4.2911.39 ± 5.06
Change from baseline to Day 2-0.40 ± 3.85-0.39 ± 3.520.68 ± 3.652.35 ± 3.90
Day 38.85 ± 4.799.42 ± 4.5310.57 ± 5.0410.12 ± 5.40
Change from baseline to Day 3-1.85 ± 3.78-1.69 ± 3.80-0.38 ± 4.461.08 ± 4.71
Day 48.24 ± 5.139.60 ± 5.0910.75 ± 5.879.34 ± 5.39
Change from baseline to Day 4-2.54 ± 5.04-1.55 ± 4.73-0.13 ± 5.270.23 ± 5.03
Day 57.90 ± 4.978.89 ± 5.569.29 ± 4.788.36 ± 4.50
Change from baseline to Day 5-2.79 ± 4.64-2.26 ± 4.98-1.58 ± 6.03-0.56 ± 4.47
Day 66.98 ± 5.097.94 ± 5.448.09 ± 4.868.24 ± 6.23
Change from baseline to Day 6-3.67 ± 5.57-3.23 ± 5.32-2.44 ± 5.56-0.71 ± 5.61
Day 76.0 ± 5.55.75 ± 3.948.39 ± 6.496.91 ± 4.57
Change from baseline to Day 7-4.65 ± 5.77-5.29 ± 4.85-2.24 ± 7.20-2.02 ± 4.58
Day 85.06 ± 4.145.82 ± 4.137.02 ± 6.255.50 ± 4.03
Change from baseline to Day 8-5.48 ± 5.34-5.38 ± 4.76-3.64 ± 6.88-3.48 ± 4.18
Day 94.44 ± 3.765.22 ± 4.346.86 ± 6.454.90 ± 2.80
Change from baseline to Day 9-6.10 ± 5.88-6.20 ± 4.75-4.00 ± 7.58-3.95 ± 4.39
Day 103.90 ± 3.624.37 ± 3.795.85 ± 6.674.00 ± 2.96
Change from baseline to Day 10-6.67 ± 5.41-6.96 ± 4.25-4.59 ± 7.56-4.77 ± 4.36
Follow-up visit 1 (Day 14)3.22 ± 3.723.39 ± 3.234.23 ± 6.193.40 ± 3.58
Change from baseline to follow-up visit 1-7.42 ± 5.74-7.90 ± 4.35-6.59 ± 7.245.21 ± 4.95
Follow-up visit 2 (Day 28/End of Study)1.84 ± 2.492.23 ± 2.852.89 ± 6.201.75 ± 2.05
Change from baseline to follow-up visit 2-8.96 ± 5.14-9.02 ± 4.26-7.78 ± 7.12-7.17 ± 4.74
Statistical analysis
  • Placebo Tablets vs 900 mg Dose vs 1800 mg Dose vs 3600 mg Dose · ANCOVA · p = 0.2
SecondaryScoring of World Health Organization (WHO) Clinical Outcome Scale (9-point Scale) at Screening, Days 1, 3, 5, End of Treatment (Day 10), Follow-Up Visit (Day 14), and Day 28

The number and percentage of patients for each WHO clinical outcome score was summarized. Scores were compared using the Mann-Whitney-Wilcoxon test. This scale is called the "WHO Clinical Outcome Scale". It is scored from 0 to 9 where 9 is the most severe disease presentation. A higher score is a worse outcome.

Time frame:
Screening (Day -2 to Day -1), Days 1, 3, 5, End of Treatment (Day 10), Follow-Up Visit (Day 14), and Day 28
Reported as:
Count of participants · Participants
Scoring of World Health Organization (WHO) Clinical Outcome Scale (9-point Scale) at Screening, Days 1, 3, 5, End of Treatment (Day 10), Follow-Up Visit (Day 14), and Day 28
ParticipantsPlacebo Tablets900 mg Dose1800 mg Dose3600 mg Dose
Screening — WHO Clinical Outcome Scale Score 00000
Screening — WHO Clinical Outcome Scale Score 118151923
Screening — WHO Clinical Outcome Scale Score 235402929
Screening — WHO Clinical Outcome Scale Score 30000
Screening — WHO Clinical Outcome Scale Score 40000
Screening — WHO Clinical Outcome Scale Score 50000
Screening — WHO Clinical Outcome Scale Score 60000
Screening — WHO Clinical Outcome Scale Score 70000
Screening — WHO Clinical Outcome Scale Score 80000
Day 1 — WHO Clinical Outcome Scale Score 00000
Day 1 — WHO Clinical Outcome Scale Score 115131718
Day 1 — WHO Clinical Outcome Scale Score 238423134
Day 1 — WHO Clinical Outcome Scale Score 30000
Day 1 — WHO Clinical Outcome Scale Score 40000
Day 1 — WHO Clinical Outcome Scale Score 50000
Day 1 — WHO Clinical Outcome Scale Score 60000
Day 1 — WHO Clinical Outcome Scale Score 70000
Day 1 — WHO Clinical Outcome Scale Score 80000
Day 3 — WHO Clinical Outcome Scale Score 00000
Day 3 — WHO Clinical Outcome Scale Score 118161519
Day 3 — WHO Clinical Outcome Scale Score 235383225
Day 3 — WHO Clinical Outcome Scale Score 30000
Day 3 — WHO Clinical Outcome Scale Score 40000
Day 3 — WHO Clinical Outcome Scale Score 50000
Day 3 — WHO Clinical Outcome Scale Score 60000
Day 3 — WHO Clinical Outcome Scale Score 70000
Day 3 — WHO Clinical Outcome Scale Score 80000
Day 5 — WHO Clinical Outcome Scale Score 00010
Day 5 — WHO Clinical Outcome Scale Score 117211219
Day 5 — WHO Clinical Outcome Scale Score 234312927
Day 5 — WHO Clinical Outcome Scale Score 30000
Day 5 — WHO Clinical Outcome Scale Score 40100
Day 5 — WHO Clinical Outcome Scale Score 50000
Day 5 — WHO Clinical Outcome Scale Score 60000
Day 5 — WHO Clinical Outcome Scale Score 70000
Day 5 — WHO Clinical Outcome Scale Score 80000
End of Treatment (Day 10) — WHO Clinical Outcome Scale Score 03551
End of Treatment (Day 10) — WHO Clinical Outcome Scale Score 129271918
End of Treatment (Day 10) — WHO Clinical Outcome Scale Score 219202231
End of Treatment (Day 10) — WHO Clinical Outcome Scale Score 31010
End of Treatment (Day 10) — WHO Clinical Outcome Scale Score 40200
End of Treatment (Day 10) — WHO Clinical Outcome Scale Score 50000
End of Treatment (Day 10) — WHO Clinical Outcome Scale Score 60000
End of Treatment (Day 10) — WHO Clinical Outcome Scale Score 70000
End of Treatment (Day 10) — WHO Clinical Outcome Scale Score 80000
Follow-up visit 1 (Day 14) — WHO Clinical Outcome Scale Score 010141213
Follow-up visit 1 (Day 14) — WHO Clinical Outcome Scale Score 131212324
Follow-up visit 1 (Day 14) — WHO Clinical Outcome Scale Score 21118811
Follow-up visit 1 (Day 14) — WHO Clinical Outcome Scale Score 30100
Follow-up visit 1 (Day 14) — WHO Clinical Outcome Scale Score 40000
Follow-up visit 1 (Day 14) — WHO Clinical Outcome Scale Score 50000
Follow-up visit 1 (Day 14) — WHO Clinical Outcome Scale Score 60000
Follow-up visit 1 (Day 14) — WHO Clinical Outcome Scale Score 70010
Follow-up visit 1 (Day 14) — WHO Clinical Outcome Scale Score 80000
Follow-up visit 2 (Day 28/End Of Study) — WHO Clinical Outcome Scale Score 028211919
Follow-up visit 2 (Day 28/End Of Study) — WHO Clinical Outcome Scale Score 120212124
Follow-up visit 2 (Day 28/End Of Study) — WHO Clinical Outcome Scale Score 251258
Follow-up visit 2 (Day 28/End Of Study) — WHO Clinical Outcome Scale Score 30000
Follow-up visit 2 (Day 28/End Of Study) — WHO Clinical Outcome Scale Score 40000
Follow-up visit 2 (Day 28/End Of Study) — WHO Clinical Outcome Scale Score 50000
Follow-up visit 2 (Day 28/End Of Study) — WHO Clinical Outcome Scale Score 60000
Follow-up visit 2 (Day 28/End Of Study) — WHO Clinical Outcome Scale Score 70000
Follow-up visit 2 (Day 28/End Of Study) — WHO Clinical Outcome Scale Score 80010
Statistical analysis
  • Placebo Tablets vs 900 mg Dose vs 1800 mg Dose vs 3600 mg Dose · Wilcoxon (Mann-Whitney) · p = 0.2
SecondaryRate of Hospitalization Through Day 28

The analysis of this endpoint was performed on the intention-to-treat (ITT) population. The percentage of patients who were hospitalized was compared using a binary logistic regression analysis. The model included only the treatment group. The results were presented as odds ratios, with associated 80% CIs and p-value.

Time frame:
Day 1 to Day 28
Reported as:
Count of participants · Participants
Rate of Hospitalization Through Day 28
ParticipantsPlacebo Tablets900 mg Dose1800 mg Dose3600 mg Dose
Yes, hospitalized2431
No, not hospitalized51514551
Statistical analysis
  • Placebo Tablets vs 900 mg Dose vs 1800 mg Dose vs 3600 mg Dose · Regression, Logistic · p = 0.2
SecondaryRate of Progression to Oxygen Therapy Through Day 28

The analysis of this endpoint was performed on the intention-to-treat (ITT) population. The number and percentage of patients who progressed to oxygen therapy was presented. The percentage of patients who had progressed to oxygen therapy was compared using a binary logistic regression analysis. The model included only the treatment group. The results were presented as odds ratios, with associated 80% confidence intervals (CIs) and p-value.

Time frame:
Day 1 to Day 28
Reported as:
Count of participants · Participants
Rate of Progression to Oxygen Therapy Through Day 28
ParticipantsPlacebo Tablets900 mg Dose1800 mg Dose3600 mg Dose
Yes, progressed to oxygen therapy1421
No, did not progress to oxygen therapy52514651
Statistical analysis
  • Placebo Tablets vs 900 mg Dose vs 1800 mg Dose vs 3600 mg Dose · Regression, Logistic · p = 0.2
SecondaryType of Oxygen Therapy Received Through Day 28

The analysis of this endpoint was performed on the intention-to-treat (ITT) population and only on those who received oxygen therapy. The number and percentage of patients who received different types of oxygen therapy was presented using descriptive statistics.

Time frame:
Day 1 to Day 28
Reported as:
Count of participants · Participants
Type of Oxygen Therapy Received Through Day 28
ParticipantsPlacebo Tablets900 mg Dose1800 mg Dose3600 mg Dose
Supplemental oxygen1411
Mechanical ventilation0010
SecondaryDuration of Hospitalization

The duration of hospitalization was performed on the intention-to-treat (ITT) population in subjects who were hospitalized. Duration of hospitalization was summarized by treatment group using descriptive statistics (N, mean, median, standard deviation, Q1, Q3, minimum, and maximum). An ANOVA model was performed to analyze the difference between treatment groups. The model included only the treatment group. Contrasts under this model allowed for the comparisons across treatment groups. The results were presented as mean treatment difference with associated 80% confidence interval (CI) and p-value.

Time frame:
Day 1 through Day 28
Reported as:
Mean · days
Duration of Hospitalization
daysPlacebo Tablets900 mg Dose1800 mg Dose3600 mg Dose
Duration of Hospitalization3.0 ± 0.05.75 ± 5.198.67 ± 12.423.0 ± 0
Statistical analysis
  • Placebo Tablets vs 900 mg Dose vs 1800 mg Dose vs 3600 mg Dose · ANOVA · p = 0.2
SecondaryMortality Rate by Day 28

The analysis of this endpoint was performed on the intention-to-treat (ITT) population. The number and percentage of patients who died was presented. The percentage of patients who died was compared using a binary logistic regression. The model included only the treatment group. Contrasts under this model allowed for the comparisons across treatment groups. The results were presented as odds ratios, with associated 80% CIs and p-values.

Time frame:
Day 1 to Day 28
Reported as:
Count of participants · Participants
Mortality Rate by Day 28
ParticipantsPlacebo Tablets900 mg Dose1800 mg Dose3600 mg Dose
No, did not die53554752
Yes, died0010
Statistical analysis
  • Placebo Tablets vs 900 mg Dose vs 1800 mg Dose vs 3600 mg Dose · Regression, Logistic · p = 0.2

Adverse events

Collected over Adverse event (AE) data were collected for approximately 1 month. All subjects were closely monitored for adverse events from informed consent for at least 18 days after the final dose of study treatment (until Day 28 ±2). Subjects who withdrew early from the study had follow-up phone calls to collect safety data until End of Study on Day 28±2.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Tablets0/53 (0%)2/53 (3.8%)29/53 (54.7%)
900 mg Dose0/55 (0%)4/55 (7.3%)27/55 (49.1%)
1800 mg Dose1/48 (2.1%)4/48 (8.3%)33/48 (68.8%)
3600 mg Dose0/52 (0%)1/52 (1.9%)46/52 (88.5%)
Most frequent serious events
Most frequent serious events
EventPlacebo Tablets900 mg Dose1800 mg Dose3600 mg Dose
Respiratory distressRespiratory, thoracic and mediastinal disorders2/533/551/480/52
PneumoniaInfections and infestations0/532/550/481/52
Proctitis ulcerativeGastrointestinal disorders0/530/551/480/52
AstheniaGeneral disorders0/530/551/480/52
Rash maculopapularRespiratory, thoracic and mediastinal disorders0/530/551/481/52
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/531/550/480/52
Deep vein thrombosisVascular disorders0/531/550/480/52
Most frequent other events
Most frequent other events
EventPlacebo Tablets900 mg Dose1800 mg Dose3600 mg Dose
DiarrheaGastrointestinal disorders10/5314/5514/4830/52
Gastrointestinal disorderGastrointestinal disorders5/536/556/4812/52
Laboratory test abnormalInvestigations7/535/555/484/52
RashSkin and subcutaneous tissue disorders3/534/555/483/52
Feces softGastrointestinal disorders2/531/554/482/52
Gastric disorderGastrointestinal disorders0/530/554/481/52
Respiratory distressRespiratory, thoracic and mediastinal disorders2/534/552/480/52
NauseaGastrointestinal disorders2/532/553/481/52

Baseline characteristics

Of the 225 randomized subjects, a total of 208 subjects received at least one dose of study medication, for which baseline data are presented here. The overall number of baseline participants in each arm reflects the number of subjects who took at least one dose of study medication in each arm, not the total number randomized in each arm.

Age, Continuous
Age, Continuous(years)Placebo Tablets900 mg Dose1800 mg Dose3600 mg DoseTotal
Mean43.9 ± 13.246.7 ± 10.442.5 ± 12.046.5 ± 11.044.9 ± 11.9
Sex: Female, Male
Sex: Female, Male(Participants)Placebo Tablets900 mg Dose1800 mg Dose3600 mg DoseTotal
Female34341928115
Male1921292493
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo Tablets900 mg Dose1800 mg Dose3600 mg DoseTotal
Hispanic or Latino22217
Not Hispanic or Latino51534650200
Unknown or Not Reported00011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo Tablets900 mg Dose1800 mg Dose3600 mg DoseTotal
American Indian or Alaska Native00000
Asian01304
Native Hawaiian or Other Pacific Islander00000
Black or African American01012
White53534551202
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Placebo Tablets900 mg Dose1800 mg Dose3600 mg DoseTotal
Canada53554852208
Smoking status
Smoking status(Participants)Placebo Tablets900 mg Dose1800 mg Dose3600 mg DoseTotal
Never smoker28332925115
Current smoker847625
Former smoker1718122168
08

Study locations

1 site
  • Institut de Cardiologie de Montréal
    Montréal, Quebec H1T 1C8, Canada
09

References and documents

Publications

  • U.S. Department of Health and Human Services, Determination of a Public Health Emergency and Declaration that Circumstances Exist Justifying Authorizations Pursuant to Section 564(b) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3. February 4, 2020.
  • Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012 Nov 29;367(22):2089-99. doi: 10.1056/NEJMoa1206797. Epub 2012 Nov 5. PubMed 23126252 ↗
  • Dai W, Zhang B, Jiang XM, Su H, Li J, Zhao Y, Xie X, Jin Z, Peng J, Liu F, Li C, Li Y, Bai F, Wang H, Cheng X, Cen X, Hu S, Yang X, Wang J, Liu X, Xiao G, Jiang H, Rao Z, Zhang LK, Xu Y, Yang H, Liu H. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020 Jun 19;368(6497):1331-1335. doi: 10.1126/science.abb4489. Epub 2020 Apr 22. PubMed 32321856 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in May 2021, 4 months.

Results were first posted in Dec 2022, 1 year 6 months after primary completion.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 4 months is below that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2020
First posted
Dec 21, 2020
StartActual
Jan 11, 2021
Primary completionActual
May 17, 2021
CompletionActual
May 17, 2021
Results first posted
Dec 7, 2022
Last update
Dec 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04676867
Lead sponsor
DalCor Pharmaceuticals
Collaborators
The Montreal Health Innovations Coordinating Center (MHICC), Covance
Responsible party
Sponsor
First posted
Dec 21, 2020
Start date
Jan 11, 2021
Primary completion
May 17, 2021
Completion
May 17, 2021
Results posted
Dec 7, 2022
Last update
Dec 7, 2022

Study contacts

David Kallend
study director · DalCor Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dalcetrapib

Start the discussion